IP Verse

Combination Of A Pd-1 Antagonist And Eribulin For Treating Cancer

Patent No. EP3265122 (titled "Combination Of A Pd-1 Antagonist And Eribulin For Treating Cancer") was filed by Eisai R&D Management on Mar 3, 2016. The application was issued on May 4, 2022.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
GENERICS UKFeb 3, 2023ELKINGTON AND FIFE
PAJAROFeb 3, 2023BIRD & BIRD
KONIG SZYNKA TILMANN VON RENESSEJan 23, 2023KONIG SZYNKA TILMANN VON RENESSE PATENTANWALTE PARTNERSCHAFT MBB DUSSELDORF
WUESTHOFF & WUESTHOFF PATENTANWALTE PARTG MBBJan 18, 2023WICHMANN

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3265122

EISAI R&D MANAGEMENT
Application Number
EP16710891A
Filing Date
Mar 3, 2016
Status
Revoked
Sep 12, 2023
Publication Date
May 4, 2022
External Links
Slate, Register , Google Patents